Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
株式のランク #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
株価
$0.00023723
最終同期: 2024-08-26
時価総額
$1.41K
変化(1日)
111.67%
変化(1年)
0.00%
FR
取引 Pharnext S.A. (ALPHA)

カテゴリー

Pharnext S.A.(ALPHA)の営業利益率
August 2026 時点の営業利益率 TTM: -238,875.82%
Pharnext S.A. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -238,875.82% です。2022 年末時点では -5,389,847.67% でした。
Pharnext S.A. の営業利益率の履歴(2012 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -238,875.82% 0.00%
2023 -238,875.82% -95.57%
2022 -5,389,847.67% 17,251.29%
2021 -31,063.10% -42.94%
2020 -54,441.83% 488.85%
2019 -9,245.42% 3,425.69%
2018 -262.23% -59.46%
2017 -646.78% 64.72%
2016 -392.66% 19.72%
2015 -327.99% 15.64%
2014 -283.64% -15.22%
2013 -334.56% 0.00%
2012 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.97% -100.00%
US
28.81% -100.00%
NL
0.00% -
CH
31.23% -100.00%
BE
0.00% -
KR
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。